Advertisement
GMAB vs PRME
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GMAB is a Hold and PRME is a Hold.
GMAB in -4.63% downward trend, sliding for three consecutive days on October 08, 2026
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where GMAB declined for three days, in 208 of 293 cases, the price declined further within the following month. The odds of a continued downward trend are 71%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 9 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 11 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
GMAB broke above its upper Bollinger Band on October 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for GMAB just turned positive on October 19, 2026. Looking at past instances where GMAB's MACD turned positive, the stock continued to rise in 26 of 43 cases over the following month. The odds of a continued upward trend are 60%.
Following a +11.71% 3-day Advance, the price is estimated to grow further. Considering data from situations where GMAB advanced for three days, in 197 of 307 cases, the price rose further within the following month. The odds of a continued upward trend are 64%.
The Aroon Indicator entered an Uptrend today. In 147 of 213 cases where GMAB Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 69%.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 3 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. GMAB’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 59 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 72 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. GMAB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock better than average.
The Tickeron Valuation Rating of 93 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.444) is normal, around the industry mean (2.904). P/E Ratio (41.171) is within average values for comparable stocks, (-0.738). Projected Growth (PEG Ratio) (4.454) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.314) among similar stocks. P/S Ratio (5.192) is also within normal values, averaging (440.869).
Momentum Indicator for PRME turns positive, indicating new upward trend
PRME saw its Momentum Indicator move above the 0 level on October 26, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 64 similar instances where the indicator turned positive. In 57 of the 64 cases, the stock moved higher in the following days. The odds of a move higher are at 89%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for PRME just turned positive on October 06, 2026. Looking at past instances where PRME's MACD turned positive, the stock continued to rise in 30 of 35 cases over the following month. The odds of a continued upward trend are 86%.
PRME moved above its 50-day moving average on October 15, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for PRME crossed bullishly above the 50-day moving average on October 09, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 9 of 13 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 69%.
Following a +11.94% 3-day Advance, the price is estimated to grow further. Considering data from situations where PRME advanced for three days, in 159 of 194 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
The Aroon Indicator entered an Uptrend today. In 98 of 114 cases where PRME Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 86%.
Bearish Trend Analysis
The 10-day RSI Indicator for PRME moved out of overbought territory on October 30, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 17 similar instances where the indicator moved out of overbought territory. In 17 of the 17 cases, the stock moved lower in the following days. This puts the odds of a move lower at 90%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 35 of 40 cases where PRME's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 88%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PRME declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.
PRME broke above its upper Bollinger Band on October 27, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 27 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.404) is normal, around the industry mean (2.904). P/E Ratio (-4.238) is within average values for comparable stocks, (-0.738). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.314) among similar stocks. P/S Ratio (128.205) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. PRME’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 94 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 95 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PRME’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
GMAB | PRME | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 37 | 30 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 93 Overvalued | 27 Undervalued | |
PROFIT vs RISK RATING 1..100 | 72 | 100 | |
SMR RATING 1..100 | 59 | 95 | |
PRICE GROWTH RATING 1..100 | 34 | 35 | |
P/E GROWTH RATING 1..100 | 3 | 94 | |
SEASONALITY SCORE 1..100 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
PRME's Valuation (27) in the null industry is significantly better than the same rating for GMAB (93). This means that PRME’s stock grew significantly faster than GMAB’s over the last 12 months.
GMAB's Profit vs Risk Rating (72) in the null industry is in the same range as PRME (100). This means that GMAB’s stock grew similarly to PRME’s over the last 12 months.
GMAB's SMR Rating (59) in the null industry is somewhat better than the same rating for PRME (95). This means that GMAB’s stock grew somewhat faster than PRME’s over the last 12 months.
GMAB's Price Growth Rating (34) in the null industry is in the same range as PRME (35). This means that GMAB’s stock grew similarly to PRME’s over the last 12 months.
GMAB's P/E Growth Rating (3) in the null industry is significantly better than the same rating for PRME (94). This means that GMAB’s stock grew significantly faster than PRME’s over the last 12 months.
| GMAB | PRME | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 51% | 2 days ago 90% |
| Stochastic ODDS (%) | 2 days ago 69% | 2 days ago 88% |
| Momentum ODDS (%) | N/A | 2 days ago 89% |
| MACD ODDS (%) | 2 days ago 60% | 2 days ago 86% |
| TrendWeek ODDS (%) | 2 days ago 70% | 2 days ago 88% |
| TrendMonth ODDS (%) | 2 days ago 65% | 2 days ago 79% |
| Advances ODDS (%) | 11 days ago 64% | 2 days ago 82% |
| Declines ODDS (%) | 29 days ago 71% | 4 days ago 88% |
| BollingerBands ODDS (%) | 2 days ago 70% | 2 days ago 90% |
| Aroon ODDS (%) | 2 days ago 69% | 2 days ago 86% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
GMAB’s FA Score shows that 1 FA rating(s) are green while PRME’s FA Score has 1 green FA rating(s).
- GMAB’s FA Score: 1 green, 4 red.
- PRME’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
GMAB’s TA Score shows that 3 TA indicator(s) are bullish while PRME’s TA Score has 6 bullish TA indicator(s).
- GMAB’s TA Score: 3 bullish, 4 bearish.
- PRME’s TA Score: 6 bullish, 4 bearish.
Price Growth
GMAB (@Biotechnology) experienced а -3.79% price change this week, while PRME (@Biotechnology) price change was -7.28% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -8.72%. For the same industry, the average monthly price growth was -14.23%, and the average quarterly price growth was -21.13%.
Reported Earning Dates
GMAB is expected to report earnings on Nov 05, 2026.
PRME is expected to report earnings on Nov 06, 2026.
Industries' Descriptions
@Biotechnology (-8.72% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
GMAB and
Correlation & Price change
A.I.dvisor indicates that over the last year, GMAB has been loosely correlated with AXON. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if GMAB jumps, then AXON could also see price increases.
| Ticker / NAME | Correlation To GMAB | 1D Price Change % | ||
|---|---|---|---|---|
| GMAB | 100% | -0.72% | ||
| AXON - GMAB | 47% Loosely correlated | +1.83% | ||
| PRME - GMAB | 42% Loosely correlated | +9.23% | ||
| VIR - GMAB | 41% Loosely correlated | +4.90% | ||
| PCVX - GMAB | 40% Loosely correlated | +8.01% | ||
| EDIT - GMAB | 39% Loosely correlated | +4.62% | ||
More | ||||
PRME and
Correlation & Price change
A.I.dvisor indicates that over the last year, PRME has been loosely correlated with CRSP. These tickers have moved in lockstep 66% of the time. This A.I.-generated data suggests there is some statistical probability that if PRME jumps, then CRSP could also see price increases.
| Ticker / NAME | Correlation To PRME | 1D Price Change % | ||
|---|---|---|---|---|
| PRME | 100% | +9.23% | ||
| CRSP - PRME | 66% Loosely correlated | +3.57% | ||
| BEAM - PRME | 64% Loosely correlated | +5.55% | ||
| RXRX - PRME | 62% Loosely correlated | +5.43% | ||
| EDIT - PRME | 62% Loosely correlated | +4.62% | ||
| RCKT - PRME | 55% Loosely correlated | +3.98% | ||
More | ||||